California Public Employees Retirement System Purchases 17,439 Shares of Illumina, Inc. $ILMN

California Public Employees Retirement System raised its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 6.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 309,145 shares of the life sciences company’s stock after buying an additional 17,439 shares during the period. California Public Employees Retirement System owned about 0.20% of Illumina worth $29,496,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of ILMN. Cerity Partners LLC increased its holdings in Illumina by 292.9% during the 2nd quarter. Cerity Partners LLC now owns 101,970 shares of the life sciences company’s stock valued at $9,729,000 after purchasing an additional 76,019 shares in the last quarter. Cresset Asset Management LLC grew its holdings in shares of Illumina by 30.9% during the second quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock worth $706,000 after purchasing an additional 1,748 shares during the last quarter. Tema Etfs LLC increased its stake in shares of Illumina by 37.6% in the second quarter. Tema Etfs LLC now owns 4,835 shares of the life sciences company’s stock valued at $461,000 after buying an additional 1,322 shares in the last quarter. Marshall Wace LLP raised its holdings in shares of Illumina by 49.0% in the second quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock valued at $5,691,000 after buying an additional 19,618 shares during the last quarter. Finally, First Trust Advisors LP raised its holdings in shares of Illumina by 50.4% in the second quarter. First Trust Advisors LP now owns 554,558 shares of the life sciences company’s stock valued at $52,910,000 after buying an additional 185,830 shares during the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on ILMN shares. Evercore ISI raised their price objective on shares of Illumina from $132.00 to $142.00 and gave the company an “outperform” rating in a research report on Friday, October 31st. TD Cowen raised their price target on shares of Illumina from $110.00 to $115.00 and gave the company a “hold” rating in a report on Friday, October 31st. Wall Street Zen upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Illumina in a report on Thursday, December 4th. Finally, JPMorgan Chase & Co. lifted their target price on Illumina from $100.00 to $105.00 and gave the company a “neutral” rating in a research note on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Illumina has an average rating of “Hold” and a consensus price target of $115.00.

Illumina Stock Performance

Shares of Illumina stock opened at $134.91 on Thursday. The firm has a fifty day moving average of $113.32 and a two-hundred day moving average of $102.00. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.12 and a current ratio of 1.43. The stock has a market capitalization of $20.61 billion, a price-to-earnings ratio of 30.25, a PEG ratio of 2.36 and a beta of 1.44. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $153.06.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.16 by $0.18. The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.07 billion. Illumina had a return on equity of 29.21% and a net margin of 16.40%.The firm’s revenue was up .4% on a year-over-year basis. During the same period last year, the company earned $1.14 EPS. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. As a group, equities research analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

Insider Activity at Illumina

In related news, Director Scott Gottlieb purchased 500 shares of the stock in a transaction dated Monday, November 3rd. The stock was bought at an average cost of $122.13 per share, with a total value of $61,065.00. Following the purchase, the director directly owned 12,523 shares in the company, valued at $1,529,433.99. The trade was a 4.16% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. 2.60% of the stock is currently owned by company insiders.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.